Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031

Second Primary Cancer Prevention Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the second primary cancer prevention market will expand from USD 18.3 billion in 2026 to USD 24.7 billion in 2031 at a CAGR of 6.1% during the forecast period.

A second primary cancer is considered to be a second cancer that occurs years after the first cancer was diagnosed and is not a recurrence of the same cancer nor a metastasis. Advances in technology and medical care have improved the ability to diagnose and treat cancer, resulting in higher survival rates for those diagnosed with cancer. With the increased number of long-term cancer survivors present, it has become increasingly important to prevent and detect second primary cancers as part of the care provided to oncology patients. Risk factors for developing a second primary cancer include a previous history of receiving radiation therapy or chemotherapy, inherited genetic defects, smoking, obesity, exposure to environmental agents, and increasing age. Preventive measures include routine screening, monitoring the survivorship health status of cancer patients, making healthy lifestyle choices, providing genetically based counselling, and implementing risk and age-based surveillance programs. The healthcare system is placing more emphasis on really providing adequate survivorship care pathways in order to promote the early identification of additional cancers; to help reduce medical problems associated with additional cancers; and to improve long-term outcomes for cancer survivors, while also reducing the costs associated with the treatment of advanced cancer.

Request a free sample copy or view the report summary: Second Primary Cancer Prevention Market Report

Second Primary Cancer Prevention Market Report Highlights

• Rising global cancer survivorship is increasing the need for long-term monitoring and second primary cancer prevention strategies.

• Growing adoption of genetic testing, risk assessment tools, and personalised surveillance programs is improving early identification of individuals at elevated risk.

• Government and healthcare organisations are strengthening survivorship care guidelines, promoting routine screening and preventive interventions among cancer survivors.

• Advances in molecular diagnostics, liquid biopsy technologies, and early detection platforms are enhancing the effectiveness of second primary cancer prevention and surveillance programs.

Second Primary Cancer Prevention Market Growth Drivers and Restraints

Growth Drivers:

• The increasing number of cancer survivors globally is a major factor driving demand for second primary cancer prevention services. Advances in early diagnosis, targeted therapies, immunotherapies, and supportive care have improved survival outcomes across multiple cancer types. As survivors live longer, the likelihood of developing a new primary malignancy increases, creating greater demand for long-term surveillance, risk assessment, and screening programs. Research from the National Cancer Institute indicates that a substantial proportion of newly diagnosed cancers occur among individuals with a previous cancer history. Consequently, healthcare providers are strengthening survivorship care models and preventive monitoring strategies.

• The growing implementation of evidence-based screening programs is supporting the expansion of second primary cancer prevention initiatives. Government health agencies continue to recommend routine screening for cancers such as breast, cervical, colorectal, and lung cancer among eligible populations. Early detection improves treatment outcomes and supports the identification of new malignancies before symptom onset. Advances in molecular diagnostics, liquid biopsy technologies, and genomic profiling are further enhancing risk stratification and surveillance capabilities. Rising awareness among healthcare professionals and cancer survivors regarding the benefits of preventive screening is expected to contribute to increased utilisation of monitoring and early detection services.

Restraints:

• Long-term surveillance programs often require repeated screening procedures, specialist consultations, diagnostic testing, and genetic assessments. These activities can increase healthcare expenditures for patients and providers. Limited reimbursement coverage and unequal access to specialised survivorship services may restrict the adoption of comprehensive second primary cancer prevention programs in some regions.

Second Primary Cancer Prevention Market Key Development

• September 2025 – Exact Sciences expanded its multi-cancer early detection (MCED) pipeline to improve the identification of new and recurrent malignancies among cancer survivors. The initiative strengthens preventive screening strategies, supports earlier intervention, and enhances long-term patient monitoring across diverse cancer types.

• May 2025 – Guardant Health introduced nearly a dozen advanced Smart Liquid Biopsy applications for its Guardant360 liquid biopsy platform. These innovations improve cancer detection, treatment selection, recurrence monitoring, and precision oncology decision-making while supporting broader preventive and surveillance programs.

• July 2025 – Illumina enhanced its genomic sequencing platforms to support large-scale cancer risk profiling and population-based screening initiatives. The advancements improve genetic risk assessment, facilitate early identification of high-risk individuals, and strengthen personalised cancer prevention strategies.

• July 2025 –Thermo Fisher Scientific expanded its diagnostic and cancer screening portfolio with advanced molecular testing solutions. The development supports wider implementation of prevention programs, improves early detection capabilities, and enables more effective risk-based screening approaches.

Second Primary Cancer Prevention Market Segmentation

Knowledge Sourcing Intelligence has segmented the Second Primary Cancer Prevention Market based on prevention type, risk category, cancer type, end user, and region:

By Prevention Type

• Screening and Early Detection

• Chemoprevention

• Lifestyle Intervention Programs

• Genetic Counselling and Testing

By Risk Category

• Treatment-Induced Risk

• Genetic Predisposition

• Lifestyle and Environmental Risk

By Cancer Type

• Breast Cancer Survivors

• Lung Cancer Survivors

• Colorectal Cancer Survivors

• Prostate Cancer Survivors

• Pediatric Cancer Survivors

• Others

By End User

• Hospitals

• Cancer Survivorship Clinics

• Diagnostic Centers

• Research Institutes

By Geography

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Second Primary Cancer Prevention Market Key Players

• Roche Holding AG

• Exact Sciences Corporation

• Guardant Health, Inc.

• Illumina, Inc.

• Thermo Fisher Scientific Inc.

• Quest Diagnostics Incorporated

• Laboratory Corporation of America Holdings

• Freenome Holdings, Inc.

• GRAIL, Inc.